Lisa Spencer
A5048111813- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Sarcoidosis and Beryllium Toxicity Research
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Long-Term Effects of COVID-19
- Medical Imaging and Pathology Studies
- Systemic Sclerosis and Related Diseases
- Inflammatory Myopathies and Dermatomyositis
- COVID-19 Clinical Research Studies
- Respiratory and Cough-Related Research
- Inhalation and Respiratory Drug Delivery
- Intensive Care Unit Cognitive Disorders
- Pleural and Pulmonary Diseases
- Eosinophilic Disorders and Syndromes
- COVID-19 and Mental Health
- Occupational and environmental lung diseases
- Pediatric health and respiratory diseases
- Pulmonary Hypertension Research and Treatments
- Transplantation: Methods and Outcomes
- Lung Cancer Treatments and Mutations
- Occupational exposure and asthma
- Sinusitis and nasal conditions
- Venous Thromboembolism Diagnosis and Management
- Frailty in Older Adults
- Blood disorders and treatments
- Neuroinflammation and Neurodegeneration Mechanisms
University of Liverpool
2016-2025
Aintree University Hospitals NHS Foundation Trust
2011-2025
Aintree University Hospital
2012-2024
NIHR Leicester Biomedical Research Centre
2023
University of Leicester
2023
Wythenshawe Hospital
2007-2023
University of Nottingham
2023
Isabela State University
2023
Interstitial Cystitis Association
2021
Oakland University
2019-2021
The impact of coronavirus disease (COVID-19) on patients with interstitial lung (ILD) has not been established.
Sarcoidosis is a highly variable, systemic granulomatous disease of hitherto unknown aetiology. The GenPhenReSa (Genotype-Phenotype Relationship in Sarcoidosis) project represents European multicentre study to investigate the influence genotype on phenotypes sarcoidosis.The baseline phenotype module comprised 2163 Caucasian patients with sarcoidosis who were phenotyped at 31 centres according standardised protocol.From this module, we found that acute onset mainly female, young and Scadding...
Rationale: Pulmonary hypertension (PH) associated with fibrotic idiopathic interstitial pneumonia (IIP; pulmonary fibrosis and nonspecific pneumonia) confers important additional morbidity mortality.Objectives: To evaluate the safety clinical efficacy of dual endothelin-1 receptor antagonist bosentan in this patient group.Methods: In a randomized, double-blind, placebo-controlled study, 60 patients IIP right heart catheter confirmed PH were randomized 2:1 to (n = 40) or placebo 20). The...
Rituximab is often used as rescue therapy in interstitial lung disease (ILD) associated with connective tissue (CTD), but has not been studied clinical trials. This study aimed to assess whether rituximab superior cyclophosphamide a treatment for severe or progressive CTD ILD.
Rationale: Shared symptoms and genetic architecture between coronavirus disease (COVID-19) lung fibrosis suggest severe acute respiratory syndrome 2 (SARS-CoV-2) infection may lead to progressive damage. Objectives: The UK Interstitial Lung Disease Consortium (UKILD) post–COVID-19 study interim analysis was planned estimate the prevalence of residual abnormalities in people hospitalized with COVID-19 on basis risk strata. Methods: PHOSP–COVID-19 (Post-Hospitalization COVID-19) used capture...
There is a major need for effective, well-tolerated treatments idiopathic pulmonary fibrosis (IPF).To assess the efficacy and safety of autotaxin inhibitor ziritaxestat in patients with IPF.The 2 identically designed, phase 3, randomized clinical trials, ISABELA 1 2, were conducted Africa, Asia-Pacific region, Europe, Latin America, Middle East, North America (26 countries). A total 1306 IPF (525 at 106 sites 781 121 2). Enrollment began November 2018 both trials follow-up was completed...
BackgroundIdiopathic pulmonary fibrosis is a progressive fibrotic lung disease, with most patients reporting cough. Currently, there are no proven treatments. We examined the use of low dose controlled-release morphine compared placebo as an antitussive therapy in individuals idiopathic fibrosis.MethodsThe PACIFY COUGH study phase 2, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial done three specialist centres UK. Eligible aged 40–90 years had diagnosis...
Abstract Aims To understand the perceptions, needs and experiences of patients with Idiopathic Pulmonary Fibrosis. Background pulmonary fibrosis is a progressive interstitial lung disease, mean life expectancy similar to some forms cancer 2–4 years from diagnosis. Unlike literature, which rich studies exploring their disease group, few publications exist on patient this severe fibrotic disease. Design A Qualitative study took place between 2007–2012. Methods Seventeen multidisciplinary team...
The COVID-19 pandemic has led to over 100 million cases worldwide. UK had 4 cases, 400 000 hospital admissions and deaths. Many patients with suffer long-term symptoms, predominantly breathlessness fatigue whether hospitalised or not. Early data suggest potentially severe consequence of is development long COVID-19-related interstitial lung disease (LC-ILD).
Background Fibrotic interstitial lung diseases (fILDs) are a heterogeneous group of associated with significant morbidity and mortality. Despite large increase in the number clinical trials last 10 years, current regulatory-approved management approaches limited to two therapies that prevent progression fibrosis. The drug development pipeline is long there an urgent need accelerate this process. This manuscript introduces concept design innovative research approach fILD: global Randomised...
Idiopathic pulmonary fibrosis is a fatal and progressive disease with limited treatment options.
Background Nintedanib slows progression of lung function decline in patients with progressive fibrosing (PF) interstitial disease (ILD) and was recommended for this indication within the United Kingdom (UK) National Health Service Scotland June 2021 England, Wales Northern Ireland November 2021. To date, there has been no national evaluation use nintedanib PF-ILD a real-world setting. Methods 26 UK centres were invited to take part service between 17 30 September 2022. Summary data regarding...
Risk factors of adverse outcomes in COVID-19 are defined but stratification mortality using non-laboratory measured scores, particularly at the time prehospital SARS-CoV-2 testing, is lacking.Multivariate regression with bootstrapping was used to identify independent predictors patients admitted an acute hospital a confirmed diagnosis COVID-19. Predictions were externally validated large random sample ISARIC cohort (N=14 231) and smaller from Aintree (N=290).983 (median age 70, IQR 53-83;...
Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic lung disease frequently complicated by gastro-oesophageal reflux disease. Although several observational studies and pilot study have investigated the role of proton pump inhibitors (PPIs) in IPF, their efficacy unknown there much debate international IPF guidelines on use. We aim to undertake an adequately powered double-blind placebo-controlled randomised multicentre clinical trial assess change forced vital...
This article is the result of a round table discussion held at BMA House. Its purpose to outline challenges facing both patients and doctors in managing idiopathic pulmonary fibrosis. A number recommendations for service development research have been identified.